Allosteric modulation of Class C GPCRs: a novel approach for the treatment of CNS disorders.
Allosteric modulation has emerged as an innovative pharmacological approach to selectively activate or inhibit several Class C GPCRs. Of the Class C GPCRs, metabotropic glutamate (mGlu) receptors represent the most promising candidates for clinical success, and both positive allosteric modulators (PAMs) and negative allosteric modulators (NAMs) of mGluRs have demonstrated therapeutic potential for a range of psychiatric and neurological disorders such as pain, depression, anxiety, cognition, Fragile X syndrome, Parkinson’s disease and schizophrenia.
Darren W
DW
Engers
Craig W
CW
Lindsley
D000494:Allosteric Regulation; D000818:Animals; D002493:Central Nervous System Diseases / Q000188:drug therapy*; D006801:Humans; D043562:Receptors, G-Protein-Coupled / Q000378:metabolism*
D043562:Receptors, G-Protein-Coupled